Qiang Yu
About
In The Last Decade
Qiang Yu
719 papers receiving 16.5k citations
Hit Papers
Peers
Comparison fields: 5 of 205
- Molecular Biology 4.9k
- Biomedical Engineering 3.4k
- Civil and Structural Engineering 1.8k
- Electrical and Electronic Engineering 1.5k
- Materials Chemistry 1.4k
Countries citing papers authored by Qiang Yu
This map shows the geographic impact of Qiang Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qiang Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qiang Yu more than expected).
Fields of papers citing papers by Qiang Yu
This network shows the impact of papers produced by Qiang Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qiang Yu. The network helps show where Qiang Yu may publish in the future.
Co-authorship network of co-authors of Qiang Yu
This figure shows the co-authorship network connecting the top 25 collaborators of Qiang Yu. A scholar is included among the top collaborators of Qiang Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qiang Yu. Qiang Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 1 | |
| 5 | 2 | |
| 6 | 0 | |
| 7 | 2 | |
| 8 | 0 | |
| 9 | 4 | |
| 10 | 1 | |
| 11 | 1 | |
| 12 | 0 | |
| 13 | 4 | |
| 14 | 129 | |
| 15 | 109 | |
| 16 | 18 | |
| 17 | 18 | |
| 18 | 9 | |
| 19 | 67 | |
| 20 | Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial | 7 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.